ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Renal Cell Carcinoma

Renal Cell Carcinoma

A subset of patients with advanced renal cell carcinoma experienced a reduction in tumor size after undergoing postprogression treatment with nivolumab.

From 1983 to 2007, the incidence of renal-malignancy end-stage renal disease has greatly increased, according to the results of a study published.

BMI was inversely correlated with serum adiponectin levels in RCC, and low BMI and high adiponectin might be associated with disease aggressiveness and survival in patients with the disease.

Updated results of the ASSURE trial showed that adjuvant sunitinib or sorafenib did not improve disease-free survival among high-risk patients with renal cell carcinoma.

Using the HDAC inhibitor vorinostat plus the VEGF inhibitor bevacizumab resulted in clinical activity in patients with clear cell renal cell carcinoma.

Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities.

Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors.

Pages

Subscribe to Renal Cell Carcinoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.